EUCTR2008-004171-21-ES进行中（未招募）不适用
Ensayo clínico en fase III de vinflunina más capecitabina frente a sólo capecitabina en pacientes con cáncer de mama avanzado previamente tratados con o resistentes a una antraciclina y que sean resistentes a taxanosA phase III trial of vinflunine + capecitabine versus capecitabine alone in patients with advanced breast cancer previously treated with or resistant to an anthracycline and who are taxane resistant
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 764
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •- Patients must give written informed consent (personally signed and dated) before completing any study-related procedure.
- •- Women with histologically or cytologically confirmed carcinoma of the breast.
- •- Documented locally recurrent or metastatic disease not amenable to curative surgery or radiotherapy.
- •- Patients must have received either one, two or three prior chemotherapy regimens including those administered in the neoadjuvant or adjuvant setting (sequential neoadjuvant/adjuvant treatment counting as one regimen.).
- •- Prior treatments must have included both an anthracycline and a taxane.
- •- Patients must have received a minimum cumulative dose of anthracycline (>or = 180 mg/m² of doxorubicin or ³ 300 mg/m² of epirubicin) or be resistant to an anthracycline according to the following criteria:
- •a) Tumour progression while on anthracycline or within 4 months of the last anthracycline dose when given in the metastatic setting* or
- •b) Recurrence while on anthracycline or within 12 months of the last anthracycline dose when given in the adjuvant or neoadjuvant setting*
- •* Note: in addition to these criteria, to be considered resistant, a patient must have received at least 2 cycles of an anthracycline-based regimen
- •- Patients must be resistant to taxane therapy according to the following criteria:
- •a) Tumour progression while on taxane or within 4 months of last taxane dose when given in the metastatic setting** or,
- •b) Recurrence while on taxane or within 12 months of the last taxane dose when given in the adjuvant setting or neoadjuvant setting**.
- •** Note: in addition to these criteria, patients taken off taxane therapy for reasons other than progression (e.g. toxicity) must have received a minimum of 3 cycles.
- •- Prior anti-cancer hormone therapy is allowed but the patient must no longer be candidate for hormone therapy. The treatment must be terminated 2 weeks prior to randomisation.
- •- Patients who have been treated with anti Her2 targeted therapy (e.g. trastuzumab, lapatinib) must have discontinued therapy at least 4 weeks days prior to randomisation.
- •- Prior radiation therapy is allowed to < 30% of the bone marrow and must be completed at least 4 weeks before randomisation.
- •- Patient must have measurable disease according to RECIST.
- •- Adequate recovery from recent surgery. At least 1 week must have elapsed from the time of minor surgery, at least 3 weeks for major surgery.
- •- Estimated life expectancy >or= 12 weeks.
- •- Karnofsky performance score >or= 70 %.
- •- Age >or= 21 years old.
- •- Adequate haematological function as defined by absolute neutrophil count (ANC) >or= 1.5 x 109/L, platelet count >or= 100 x109/L and hemoglobin >or= 10 g/dL (within 7 days before first study treatment).
- •- Adequate hepatic function as defined by: total bilirubin - Adequate renal function as defined by a calculated creatinine clearance >or= 50 mL/min according to Cockroft-Gault formula (ml/min) = [(0.85)(140-age)(weight)]/[(0.81)(SrCr µmol/L)] (within 7 days before first treatment administration).
- •- ECG without clinically relevant abnormality (within 7 days before first treatment administration).
- •- Patients on coumadin or warfarin must be on stable doses and have an International Normalized Ratio (INR) - Women
排除标准
- •- Patients with known or with clinical evidence of brain metastasis or leptomeningeal involvement.
- •- Inflammatory breast cancer without evidence of metastatic disease.
- •- Patients having received any other experimental or anti-cancer therapy within 30 days before randomisation except hormone therapy.
- •- History of second primary malignancy, except: bilateral breast carcinoma, in situ carcinoma of the cervix, adequately treated non melanomatous carcinoma of the skin, and other malignancy treated at least 5 years previously with no evidence of recurrence.
- •- Patients having as the sole tumour lesion, any of the following: malignant effusion, lymphangitis, cystic lesion, bone lesion; and any other lesion that is not assessed by imaging techniques or colour photography.
- •- Patients with pre-existing motor/sensory peripheral neuropathy of CTCAE version 3.0 grade > 1.
- •- Patients having received > 3 regimens of chemotherapy
- •- Prior therapy with capecitabine and/or vinca alkaloids (including vinflunine).
- •- History of severe hypersensitivity to vinca alkaloids and/or to fluoropyrimidine or any contra indication to any of the study drugs.
- •- Known or suspected dihydropyrimidine dehydrogenase (DPD) deficiency.
- •- Pregnant or breast feeding women.
- •- Positive pregnancy test at inclusion.
- •- Known history of HIV infection.
- •- Inability to take and/or absorb oral medication including previous gastric surgery or any evidence of partial oesophageal, gastric, small or large bowel obstruction; gastrointestinal disorder that affect the absorption of capecitabine (malabsorption syndrome, 2/3 gastric resection and bowel resection).
- •- Patients who have any serious, concurrent uncontrolled medical disorder especially uncontrolled hypercalcaemia, congestive heart failure, uncontrolled high-risk hypertension, arrhythmia, angina pectoris or previous history of myocardial infarction within 6 months prior to randomisation
- •- Prior bone marrow transplantation or autologous stem cell infusion following high-dose chemotherapy.
研究者
相似试验
进行中（未招募）
不适用
Ensayo clínico en fase III de vinflunina IV frente a un agente alquilante en pacientes con cáncer de mama metastásico previamente tratado con o resistente a una antraciclina, un taxano, un antimetabolito y un alcaloide de la vincaPhase III trial of IV vinflunine versus an alkylating agent in patients with metastatic breast cancer previously treated with or resistant to an anthracycline, a taxane, an antimetabolite, and a vinca-alkaloid (study L00070 IN 308 B0)Cáncer de mama metastásicoMetastatic breast cancerMedDRA version: 11.0Level: LLTClassification code 10055113Term: <Manually entered code. Term in E.1.1>EUCTR2009-011118-47-ESPIERRE FABRE MEDICAMENT586
进行中（未招募）
1 期
Ensayo en fase III de vinflunina más gemcitabina frente a paclitaxel más gemcitabina en pacientes con cáncer de mama irresecable, localmente recurrente o metastásico, tras quimioterapia adyuvante previa basada en antraciclinasTratamiento de pacientes con cáncer de mama irresecable, localmente recurrente o metastásico, tras quimioterapia adyuvante basada en antraciclina o, si estuviera contraindicada, una quimioterapia sin antraciclina.MedDRA version: 7.1Level: LLTClassification code 10027475EUCTR2006-001139-23-ESPierre Fabre Médicament994
进行中（未招募）
1 期
Estudio en fase II de Vinflunina administrada por vía intravenosa (IV) a pacientes con un carcinoma de células transicionales (CCT) del urotelio localmente avanzado o metastásico.Protocolo revisado 01, version 2.0 que incorpora la enmienda 04, yEnmienda de muestras para farmacogenética #01, del 18-Oct-04Enmienda de muestras de tejido del tumor primario #02, del 18-Oct-04Enmienda de muestras farmacocinéticas #03, del 18-Oct-04Cáncer Avanzado, grado IV, NosEUCTR2005-001463-64-ESBristol-Myers Squibb International Corporation160
已完成
不适用
A Phase III Trial of Vinflunine Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer Previously Treated With or Resistant to an Anthracycline and Who Are Taxane Resistant.PER-079-10PIERRE FABRE MEDICAMENT,
已完成
3 期
A clinical trial to compare the effects of two chemotherapy regimens (vinflunine plus capecitabine versus capecitabine alone) in patients with advanced breast cancer.CTRI/2009/091/000607Institut de Recherche Pierre Fabre764